Tuesday's top analyst upgrades and downgrades included Broadcom, Carrier Global, Canadian Pacific Railway, Coca-Cola, Eli Lilly, Marvell Technology, Pfizer, Regions Financial, Stryker, Synchrony Financial, Tesla and Zillow.
Monday afternoon's top analyst upgrades and downgrades included Activision Blizzard, Lucid, Nokia, Pfizer, SoFi Technologies, Sunrun and Welltower.
Monday’s top analyst upgrades and downgrades included Apple, Coca-Cola, CommScope, Coupa Software, GoPro, HubSpot, Merck, NetApp, Pfizer, Shopify, Spirit Airlines and Warner Music.
Thursday afternoon's top analyst upgrades and downgrades included AbbVie, Allstate, Amgen, Occidental Petroleum, Pfizer, SunPower, Twilio and Yum! Brands.
Broadcom, Pfizer and these other top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
These five stay-at-home and pharmaceutical stocks perhaps make sense now, on concerns over the Omicron variant of COVID-19. They are Buy rated and pay solid dividends, and they may be solid ideas…
Friday's top analyst upgrades and downgrades included Arista Networks, DataDog, FedEx, Fiserv, Gilead Sciences, Global Payments, Nvidia, Oatly, Pfizer, Target, TJX Companies and Victoria’s Secret.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 400,000 shares of Pfizer on November 11.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 140,000 shares of Pfizer on November 10.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 230,000 shares of Pfizer on November 9.
An oil and gas supermajor looking to transform its business, a Dow component and a struggling athletic gear company are reporting earnings before markets open Tuesday.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 180,000 shares of Pfizer on September 7.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 380,000 shares of Pfizer on September 1.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 350,000 shares of Pfizer on August 27.
One of Cathie Wood's ARK Invest exchange-traded funds bought over 170,000 shares of Pfizer on August 26.
